Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KLRS Kalaris Therapeutics	$2.51 +2.0%	$2.56	$2.14 ▼ $24.15	$46.94M	0.49	47,049 shs	67,709 shs
LGVN Longeveron	$0.80 0.0%	$1.29	$0.63 ▼ $2.67	$12.14M	0.23	1.93 million shs	556,700 shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	1 shs
PYRGF PyroGenesis Canada	$0.22 +6.2%	$0.31	$0.21 ▼ $0.71	$42.03M	0.83	13,160 shs	32,352 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KLRS Kalaris Therapeutics	0.00%	+2.03%	-11.62%	-10.04%	+250,999,900.00%
LGVN Longeveron	0.00%	+5.24%	-52.67%	-40.76%	-68.76%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	+4,900.00%
PYRGF PyroGenesis Canada	0.00%	-13.17%	-25.30%	-31.43%	-63.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KLRS Kalaris Therapeutics	1.2714 of 5 stars	2.0	0.0	0.0	0.0	1.6	3.3	0.6
LGVN Longeveron	3.4304 of 5 stars	3.5	5.0	0.0	0.0	1.7	1.7	1.3
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	19.52% Upside
LGVN Longeveron	3.00	Buy	$7.25	806.48% Upside
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LGVN, KLRS, NBRV, and PYRGF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LGVN Longeveron	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$2.84 per share	N/A
LGVN Longeveron	$2.39M	5.08	N/A	N/A	$0.83 per share	0.96
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00
PYRGF PyroGenesis Canada	$9.14M	4.60	N/A	N/A	($0.01) per share	-22.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-81.02%	-65.15%	N/A
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-894.40%	-95.91%	-79.69%	11/11/2025 (Estimated)
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.03	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A

Latest LGVN, KLRS, NBRV, and PYRGF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	KLRS Kalaris Therapeutics	-$0.51	-$0.61	-$0.10	-$0.61	N/A	N/A
8/13/2025	Q2 2025	LGVN Longeveron	-$0.35	-$0.33	+$0.02	-$0.33	$0.41 million	$0.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KLRS Kalaris Therapeutics	N/A	11.98	11.98
LGVN Longeveron	N/A	3.43	3.43
NBRV Nabriva Therapeutics	0.12	0.85	0.52
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KLRS Kalaris Therapeutics	66.05%
LGVN Longeveron	10.01%
NBRV Nabriva Therapeutics	0.27%
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
KLRS Kalaris Therapeutics	74.99%
LGVN Longeveron	11.20%
NBRV Nabriva Therapeutics	1.63%
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
LGVN Longeveron	20	15.18 million	13.48 million	Not Optionable
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable
PYRGF PyroGenesis Canada	90	187.53 million	96.34 million	No Data

LGVN, KLRS, NBRV, and PYRGF Headlines

Recent News About These Companies

PyroGenesis Announces Second Quarter 2025 Results

August 6, 2025 | globenewswire.com

PyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch Technology

August 5, 2025 | globenewswire.com

PyroGenesis Canada (NASDAQ:PYRGF) Stock Price Down 1% - Here's What Happened

August 3, 2025 | marketbeat.com

PyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

August 1, 2025 | globenewswire.com

PyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing Company

July 31, 2025 | globenewswire.com

PyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed Silica

July 28, 2025 | globenewswire.com

PyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata Steel

July 15, 2025 | globenewswire.com

PyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production Cycles

July 8, 2025 | globenewswire.com

PyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in Europe

July 2, 2025 | globenewswire.com

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - Morningstar

June 29, 2025 | morningstar.comM

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders

June 27, 2025 | globenewswire.com

PyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global Supplier

June 12, 2025 | globenewswire.com

PyroGenesis Announces Extension to Term of Warrants

June 9, 2025 | globenewswire.com

High-Tech Micro Cap Rallies After Securing Boeing Supplier Status

May 29, 2025 | msn.com

PyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica Samples

May 28, 2025 | globenewswire.com

PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

May 21, 2025 | globenewswire.com

PyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant Baghouse

May 15, 2025 | globenewswire.com

PyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PyroGenesis Announces First Quarter 2025 Results

May 13, 2025 | globenewswire.com

PyroGenesis Provides Update on Fumed Silica Project

May 13, 2025 | globenewswire.com

PyroGenesis Closes $2,385,000 First Tranche in Previously Announced Loan

May 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, KLRS, NBRV, and PYRGF Company Descriptions

Kalaris Therapeutics NASDAQ:KLRS

$2.51 +0.05 (+2.03%)

As of 08/22/2025 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Longeveron NASDAQ:LGVN

$0.80 0.00 (-0.03%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+1.28%)

As of 08/22/2025 07:51 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

PyroGenesis Canada NASDAQ:PYRGF

$0.22 +0.01 (+6.21%)

As of 08/22/2025 03:55 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time